|
1
|
Dowsett M, Cuzick J, Ingle J, Coates A,
Forbes J, Bliss J, Buyse M, Baum M, Buzdar A, Colleoni M, et al:
Meta-analysis of breast cancer outcomes in adjuvant trials of
aromatase inhibitors versus tamoxifen. J Clin Oncol. 28:509–518.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Carey LA, Dees EC, Sawyer L, Gatti L,
Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML and Perou
CM: The triple negative paradox: Primary tumor chemosensitivity of
breast cancer subtypes. Clin Cancer Res. 13:2329–2334. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Silver DP, Richardson AL, Eklund AC, Wang
ZC, Szallasi Z, Li Q, Juul N, Leong CO, Calogrias D, Buraimoh A, et
al: Efficacy of neoadjuvant Cisplatin in triple-negative breast
cancer. J Clin Oncol. 28:1145–1153. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Reis-Filho JS and Tutt AN: Triple negative
tumours: A critical review. Histopathology. 52:108–118. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Baselga J, Gómez P, Greil R, Braga S,
Climent MA, Wardley AM, Kaufman B, Stemmer SM, Pego A, Chan A, et
al: Randomized phase II study of the anti-epidermal growth factor
receptor monoclonal antibody cetuximab with cisplatin versus
cisplatin alone in patients with metastatic triple-negative breast
cancer. J Clin Oncol. 31:2586–2592. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Scaling AL, Prossnitz ER and Hathaway HJ:
GPER mediates estrogen-induced signaling and proliferation in human
breast epithelial cells and normal and malignant breast. Horm
Cancer. 5:146–160. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Steiman J, Peralta EA, Louis S and Kamel
O: Biology of the estrogen receptor, GPR30, in triple negative
breast cancer. Am J Surg. 206:698–703. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Girgert R, Emons G and Gründker C:
Inactivation of GPR30 reduces growth of triple-negative breast
cancer cells: Possible application in targeted therapy. Breast
Cancer Res Treat. 134:199–205. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Girgert R, Emons G and Gründker C:
Inhibition of GPR30 by estriol prevents growth stimulation of
triple-negative breast cancer cells by 17β-estradiol. BMC Cancer.
14:9352014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Vivacqua A, Lappano R, De Marco P, Sisci
D, Aquila S, De Amicis F, Fuqua SA, Andó S and Maggiolini M: G
protein-coupled receptor 30 expression is up-regulated by EGF and
TGF alpha in estrogen receptor alpha-positive cancer cells. Mol
Endocrinol. 23:1815–1826. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Nielsen TO, Hsu FD, Jensen K, Cheang M,
Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler
L, et al: Immunohistochemical and clinical characterization of the
basal-like subtype of invasive breast carcinoma. Clin Cancer Res.
10:5367–5374. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Girgert R, Emons G and Gründker C:
17β-estradiol-induced growth of triple-negative breast cancer cells
is prevented by the reduction of GPER expression after treatment
with gefitinib. Oncol Rep. 37:1212–1218. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Divisova J, Kuiatse I, Lazard Z, Weiss H,
Vreeland F, Hadsell DL, Schiff R, Osborne CK and Lee AV: The growth
hormone receptor antagonist pegvisomant blocks both mammary gland
development and MCF-7 breast cancer xenograft growth. Breast Cancer
Res Treat. 98:315–327. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Perez R, Schally AV, Vidaurre I, Rincon R,
Block NL and Rick FG: Antagonists of growth hormone-releasing
hormone suppress in vivo tumor growth and gene expression in triple
negative breast cancers. Oncotarget. 3:988–997. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Neggers SJ, Franck SE, de Rooij FW,
Dallenga AH, Poublon RM, Feelders RA, Janssen JA, Buchfelder M,
Hofland LJ, Jorgensen JO, et al: Long-term efficacy and safety of
pegvisomant in combination with long-acting somatostatin analogs in
acromegaly. J Clin Endocrinol Metab. 99:3644–3652. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Neggers SJ and van der Lely AJ:
Somatostatin analog and pegvisomant combination therapy for
acromegaly. Nat Rev Endocrinol. 5:546–552. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kireeva ML, Mo FE, Yang GP and Lau LF:
Cyr61, a product of a growth factor-inducible immediate-early gene,
promotes cell proliferation, migration, and adhesion. Mol Cell
Biol. 16:1326–1334. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Girgert R, Bartsch C, Hill SM, Kreienberg
R and Hanf V: Tracking the elusive antiestrogenic effect of
melatonin: A new methodological approach. Neuro Endocrinol Lett.
24:440–444. 2003.PubMed/NCBI
|
|
19
|
Filardo EJ, Quinn JA, Frackelton AR Jr and
Bland KI: Estrogen action via the G protein-coupled receptor,
GPR30: Stimulation of adenylyl cyclase and cAMP-mediated
attenuation of the epidermal growth factor receptor-to-MAPK
signaling axis. Mol Endocrinol. 16:70–84. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ignatov A, Ignatov T, Weissenborn C,
Eggemann H, Bischoff J, Semczuk A, Roessner A, Costa SD and
Kalinski T: G-protein-coupled estrogen receptor GPR30 and tamoxifen
resistance in breast cancer. Breast Cancer Res Treat. 128:457–466.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Contreras B and Talamantes F: Growth
hormone (GH) and 17beta-estradiol regulation of the expression of
mouse GH receptor and GH-binding protein in cultured mouse
hepatocytes. Endocrinology. 140:4725–4731. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Slootweg MC, Swolin D, Netelenbos JC,
Isaksson OG and Ohlsson C: Estrogen enhances growth hormone
receptor expression and growth hormone action in rat osteosarcoma
cells and human osteoblast-like cells. J Endocrinol. 155:159–164.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Birzniece V, Sata A and Ho KK: Growth
hormone receptor modulators. Rev Endocr Metab Disord. 10:145–156.
2009. View Article : Google Scholar : PubMed/NCBI
|
